One phase II study by Xiong et al. using cetuximab plus gemcitabine to treat EGFR-expressing advanced pancreatic cancer showed promising results with 63% of the 41 patients enrolled achieving stable disease, although subsequent studies have failed to replicate this [62,63,64,65]. Here, EGFR is linked to pancreatic neoplasm.